PPAR Agonists

Single, dual and pan-PPAR agonists are under development for the pharmacological treatment of NASH, we bring you the latest videos on this.

Interactions between gut microbiota and PPARs in NAFLD

Dr. Nicolas Lanthier (Belgium) reviews the interaction between the gut microbiota and PPARs in NAFLD. He discusses the microbiota and its link to NAFLD and IR, where he explains the key role of the gut microbes in the metabolism of their host and highlights how liver becomes the first organ to be exposed to gut changes.
View More ⏩Interactions between gut microbiota and PPARs in NAFLD
Prof. Sven Francque

Nonalcoholic steatohepatitis: the role of PPARs (Peroxisome proliferator-activated receptors)

Prof Sven Francque, Belgium, shares highlights from a recent paper in Nature reviews. PPARs regulate metabolism, inflammation and fibrosis, all of which determine NASH progression. Both PPARα-β/δ dual agonism as well as PPARγ agonism have shown beneficial effects on liver histology in phase IIb clinical trials for NASH.
View More ⏩Nonalcoholic steatohepatitis: the role of PPARs (Peroxisome proliferator-activated receptors)

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES